WIRE — Drug and supplement producer Biofarm (stock symbol: BIO), which was recently acquired by Polish group Polpharma for RON1.3 billion, had a net profit of RON26.4 million in January-June 2026, down 46% year-over-year, as per the company's half-yearly financial report sent to the Bucharest Stock Exchange on August 14.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.